Mabpro

Executive Summary

Mabpro, a.s. is a Slovakian biotechnology company focused on developing personalized immunotherapy and companion diagnostics for aggressive, hypoxic tumors. Its platform targets Carbonic Anhydrase IX (CA IX), a protein overexpressed in the tumor microenvironment under low-oxygen conditions. By combining targeted antibodies with advanced patient stratification, Mabpro aims to fill a treatment gap for cancers with poor prognosis, such as renal cell carcinoma and other solid tumors. Founded in 2006, the private company is headquartered in Bratislava and operates in the antibodies and biologics categories, though its stage and financial details remain undisclosed. Despite limited public information, its niche targeting CA IX positions it in a competitive yet underexplored area of immuno-oncology. The company's success hinges on advancing its preclinical/early clinical pipeline and securing partnerships or funding to support development. With no disclosed pipeline milestones, near-term catalysts are uncertain, but the platform's potential to address hypoxic tumors offers a unique value proposition. However, the lack of transparent data and early-stage nature introduce significant risk, warranting a cautious conviction score.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase I Clinical Trial for Lead Anti-CA IX Antibody40% success
• Q2 2026Presentation of Preclinical Data at Major Oncology Conference60% success
• Q3 2026Partnership or Licensing Deal for Companion Diagnostic Development35% success